相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Skeletal health in adults with HIV infection
Mark J. Bolland et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhong-Ning Zhu et al.
BONE (2014)
The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial
Andrew Grey et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Intensive Glycemic Control and Thiazolidinedione Use: Effects on Cortical and Trabecular Bone at the Radius and Tibia
Ann V. Schwartz et al.
CALCIFIED TISSUE INTERNATIONAL (2013)
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial
G. A. Bray et al.
DIABETES OBESITY & METABOLISM (2013)
Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women With Type 2 Diabetes Mellitus
John P. Bilezikian et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus
A. H. van Lierop et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Bone Effects of Rosiglitazone in HIV-Infected Patients With Lipoatrophy
Allison C. Ross et al.
HIV CLINICAL TRIALS (2012)
Osteoblast physiology in normal and pathological conditions
Anna Neve et al.
CELL AND TISSUE RESEARCH (2011)
Effect of Rosiglitazone on Bone Quality in a Rat Model of Insulin Resistance and Osteoporosis
Laura D. Sardone et al.
DIABETES (2011)
A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients
J. L. C. Borges et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy
Kim Henriksen et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2011)
Rosiglitazone Decreases Bone Mass and Bone Marrow Fat
Torben Harslof et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
Astrid K. Stunes et al.
BMC ENDOCRINE DISORDERS (2011)
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206
Marisa Tungsiripat et al.
AIDS (2010)
The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Increases Bone Resorption in Women with Type 2 Diabetes: A Randomized, Controlled Trial
Ugis Gruntmanis et al.
CALCIFIED TISSUE INTERNATIONAL (2010)
Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study
Zehra Berberoglu et al.
CLINICAL ENDOCRINOLOGY (2010)
Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression
G. Mabilleau et al.
DIABETIC MEDICINE (2010)
Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Bernard Zinman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus
I. Kanazawa et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Yoon K. Loke et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes An Overview of Data from PROactive
John Dormandy et al.
DRUG SAFETY (2009)
The Effect of Rosiglitazone on Insulin Sensitivity, Beta Cell Function, Bone Mineral Density, and Body Composition in HIV-positive Patients on Highly-active Antiretroviral Therapy (HAART)
K. Schindler et al.
HORMONE AND METABOLIC RESEARCH (2009)
A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes
Daniel H. Solomon et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study
Ian J. Douglas et al.
PLOS MEDICINE (2009)
Imputation methods for missing outcome data in meta-analysis of clinical trials
Julian P. T. Higgins et al.
CLINICAL TRIALS (2008)
Rosiglitazone-associated fractures in type 2 diabetes - An analysis from a diabetes outcome progression trial (ADOPT)
Steven E. Kahn et al.
DIABETES CARE (2008)
Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: A randomized, placebo-controlled trial
Dorte Glintborg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Skeletal consequences of thiazolidinedione therapy
A. Grey
OSTEOPOROSIS INTERNATIONAL (2008)
PPAR-γ regulates osteoclastogenesis in mice
Yihong Wan et al.
NATURE MEDICINE (2007)
Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells
S. Benvenuti et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2007)
Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women
Zehra Berberoglu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women:: A randomized, controlled trial
Andrew Grey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
The DREAM trial - Reply
Hertzel C. Gerstein et al.
LANCET (2006)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Thiazolidinedione use and bone loss in older diabetic adults
Ann V. Schwartz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus
P Gerdhem et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis
MA Sorocéanu et al.
JOURNAL OF ENDOCRINOLOGY (2004)
Risk factors for longitudinal bone loss in elderly men and women: The Framingham Osteoporosis Study
MT Hannan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Biochemical markers as predictors of rates of bone loss after menopause
A Rogers et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
The use of biochemical markers of bone turnover in osteoporosis
PD Delmas et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Diagnosis of osteoporosis: Respective roles of biomarkers and bone density measurements: State of the art
PD Delmas
OSTEOPOROSIS INTERNATIONAL (2000)
分享论文
